NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $459.24 +7.12 (+1.57%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDGL alerts:Sign Up Key Stats Today's Range$453.19▼$471.5050-Day Range$452.12▼$546.9352-Week Range$393.61▼$615.00Volume98,020 shsAverage Volume330,686 shsMarket Capitalization$10.61 billionP/E RatioN/ADividend YieldN/APrice Target$699.20Consensus RatingModerate Buy Company Overview Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for chronic liver diseases. The company’s primary focus is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to significant liver fibrosis, cirrhosis and other complications. Madrigal’s lead product, Rezdiffra (resmetirom), is an oral thyroid hormone receptor beta agonist. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis. The therapy is designed to address liver fat and fibrosis associated with the disease. Headquartered in Conshohocken, Pennsylvania, Madrigal markets Rezdiffra in the United States and continues to pursue the development and potential international expansion of its liver disease portfolio. William Sibold serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreMDGL MarketRank™: 2.95067915073 of 5 starsMadrigal Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 401st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 15 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMadrigal Pharmaceuticals has a consensus price target of $710.20, representing about 57.1% upside from its current price of $452.12.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($7.03) to $5.55 per share.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 17.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.59% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 9.78.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,581,182.00 in company stock.Percentage Held by Insiders17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDGL Stock News HeadlinesHead to Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Aurinia Pharmaceuticals (NASDAQ:AUPH)October 12 at 2:15 AM | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)October 10, 2026 | theglobeandmail.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year RunOctober 8, 2026 | uk.finance.yahoo.comMadrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In FocusOctober 8, 2026 | finance.yahoo.comIs Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?October 7, 2026 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. Announces Publication In The Journal Of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsOctober 6, 2026 | marketscreener.comMMadrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsOctober 6, 2026 | globenewswire.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $582.34 at the start of the year. Since then, MDGL stock has decreased by 22.4% and is now trading at $452.12. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.68) by $0.69. Madrigal Pharmaceuticals's revenue for the quarter was up 71.2% compared to the same quarter last year. Read the conference call transcript. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional investors include Sivik Global Healthcare LLC (0.01%), Krilogy Financial LLC, NorthCrest Asset Manangement LLC and Farther Finance Advisors LLC. Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, William John Sibold, Paul A Friedman, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Shannon T Kelley, Fred B Craves, David Soergel, Robert E Waltermire, Kenneth Bate and James M Daly. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Tesla (TSLA), Incyte (INCY) and Intel (INTC). Company Calendar Last Earnings7/30/2026Today10/14/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MDGL's financial health is in the Green zone, according to TradeSmith. MDGL has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees915Year Founded2011Price Target and Rating Average Price Target for Madrigal Pharmaceuticals$699.20 High Price Target$962.00 Low Price Target$542.00 Potential Upside/Downside+52.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($12.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$288.28 million Net Margins-25.32% Pretax Margin-25.32% Return on Equity-56.65% Return on Assets-25.53% Debt Debt-to-Equity Ratio0.65 Current Ratio3.20 Quick Ratio2.94 Sales & Book Value Annual Sales$958.40 million Price / Sales11.06 Cash FlowN/A Price / Cash FlowN/A Book Value$26.54 per share Price / Book17.28Miscellaneous Outstanding Shares23,100,000Free Float19,038,000Market Cap$10.60 billion OptionableOptionable Beta-1.04 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MDGL) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredForget Biotech Stocks… This Is the Smarter PlayNVIDIA, Shopify, and TSMC built fortunes by powering innovation rather than betting on a single winner. One li...Compounding Quality | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
